GHP Q3 2018

28 GHP / Q3 2018 , ROX ® Medical has developed an implantable device and therapy intended to treat uncontrolled high blood pressure. Blood pressure reduction is achieved by diverting a small amount of blood flow from the arterial system into the venous system. On the 14th August 2018, the privately held medical device company pioneering a minimally- invasive therapy for hypertension, ROX Medical, Inc. (ROX) announced the appointment of Mike MacKinnon as its Chief Executive Officer. “Despite the many classes of drugs available to physicians to treat hypertension, millions of patients still have blood pressures that are uncontrolled or resistant to treatment, leading to serious conditions including stroke, heart attack, heart failure and kidney disease,” said Mr. MacKinnon. “By diverting blood from the arteries to the veins via a small stent in a short, outpatient procedure, the impact of the ROX Coupler device on blood pressure has been shown to be long-lasting and immediate. I am excited to work with the physician-investigators on the FDA-approved US pivotal study to build the evidence for this potentially life-saving technology.” Mr. MacKinnon joins ROX from Philips North America where he was Head of Sales for Image Guided Technologies, Devices. He joined Philips through the acquisition of Volcano where he was General Manager of Phoenix Atherectomy and Peripheral Sales Leader. In 2014, Volcano acquired AtheroMed where Mike was President and CEO. Prior to AtheroMed, Mr. MacKinnon held various leadership positions with Hansen Medical, Access Closure and FoxHollow Technologies. “Mike is a seasoned medical device executive whose expertise lies in commercialising game-changing cardiovascular technologies,” commented Board Member David McIntyre. “We are thrilled to bring Mike’s leadership and energy to the ROX team as this technology progresses to the market and potentially becomes the standard of care in hypertension.” ROXMedical Appoints Mike MacKinnon as Chief Executive Officer